Circio Holding ASA — Targovax — Investor Day (2021)

4 slides from Circio Holding ASA's investor day presentation, 2021

Slide 1: Closing remarks
Closing remarks ° targovax °
Slide 2: Track record of strong execution with upcoming value inflection points
TRACK RECORD OF STRONG EXECUTION WITH UPCOMING VALUE INFLECTION POINTS 2020 2021 H1 H2 Melanoma ✓ Melanoma Part 2 data Prepare and set up new trial Mesothelioma ✓ Mesothelioma ✓ Mesothelioma ONCOS-102 Merck collaboration Fast Track designation 24-month survival 18 month survival follow-up follow-up
Slide 3: Clinical and preclinical pipeline
CLINICAL AND PRECLINICAL PIPELINE Product candidate Preclinical Phase 1 Phase 2 Collaborator Next expected event Melanoma 1H 2022 Combination w/anti PD1 First patient Colorectal cancer Updates by collaborator ONCOS-102 Combination w/Imfinzi expected 1H22 Mesothelioma 1H 2021 Combination w/pemetrexed
Slide 4: Early-stage development successfully completed – entering late-stage development
EARLY-STAGE DEVELOPMENT SUCCESSFULLY COMPLETED – ENTERING LATE-STAGE DEVELOPMENT Expansion opportunities Late-stage development Mesothelioma Colorectal cancer Early-stage development PD1 refractory melanoma Other indications Other IO combinations Clinical efficacy Platform development Immune activat